Positive top line data from the MelaFind pivotal study were announced in February 2009 and subsequently presented at several major international dermatology meetings in March and May 2009, said Electro-Optical Sciences. The company added that its final analysis of the data demonstrated that for all subgroups analyzed, the sensitivity of MelaFind was greater than 95% and MelaFind specificity was statistically significantly higher than that of study clinicians. The FDA has previously granted expedited review for the MelaFind premarket approval (PMA). Joseph Gulfo, president and CEO of Electro-Optical Sciences, said: "We believe the final results of the MelaFind pivotal study met the study endpoints and that the pivotal trial satisfied the specifications of the protocol agreement with the FDA under which it was conducted. We look forward to working with the FDA in the review of the MelaFind application." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon For full details on Electro-Optical Sciences Inc (MELA) click here. Electro-Optical Sciences Inc (MELA) has Short Term PowerRatings of 6. Details on Electro-Optical Sciences Inc (MELA) Short Term PowerRatings is available at This Link.
![]()
Email Print Archives Feedback Email Article Link
Close X
Most Popular News
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|